Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
solu medrol
The First People's Hospital of Lianyungang
Immunosuppression
1 trial -
standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT
The First People's Hospital of Lianyungang
Tumor
1 trial -
succimer
Ultragenyx UK Limited
Lead Poisoning
1 trial -
tacrolimus
The First People's Hospital of Lianyungang
Renal Transplantation
1 trial -
telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)
Praxis Precision Medicines
Telemedicine
1 trial -
telmisartan
The First People's Hospital of Lianyungang
Hypertension
1 trial -
the absorbable hemostat and suture
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ovarian Cyst Benign
1 trial -
the ginsenoside Rg3
The First People's Hospital of Lianyungang
Stage I Hepatocellular Carcinoma
1 trial -
thyrotropin-releasing hormone
Ultragenyx UK Limited
Respiratory Distress Syndrome
1 trial -
thyroxine
The First People's Hospital of Lianyungang
Hypothyroidism
1 trial -
traditional chinese medicine Xuanfei-Zhike formula
The First People's Hospital of Lianyungang
Cough Variant Asthma
1 trial -
vats
The First People's Hospital of Lianyungang
NSCLC
1 trial -
xDRIVE Tumor Profiling
The First People's Hospital of Lianyungang
Cancer
1 trial -
zanubrutinib 160 mg BID orally
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma
1 trial -
zanubrutinib, bendamustine, and obinutuzumab
The First People's Hospital of Lianyungang
Follicular Lymphoma
1 trial -
zoledronate therapy
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
zuojinwan
The First People's Hospital of Lianyungang
Functional Dyspepsia
1 trial -
Ξ²-hydroxy Ξ²-methylbutyrate (HMB) supplement
Chinese University of Hong Kong
Sarcopenia
1 trial -
Ξ³-globin reactivated autologous hematopoietic stem cells
The First People's Hospital of Lianyungang
Thalassemia Major
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources